nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—SLC6A4—chronic obstructive pulmonary disease	0.411	1	CbGaD
Levomilnacipran—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0453	0.118	CbGbCtD
Levomilnacipran—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0453	0.118	CbGbCtD
Levomilnacipran—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0409	0.106	CbGbCtD
Levomilnacipran—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0344	0.0896	CbGbCtD
Levomilnacipran—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0344	0.0896	CbGbCtD
Levomilnacipran—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0307	0.0799	CbGbCtD
Levomilnacipran—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0289	0.0752	CbGbCtD
Levomilnacipran—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0195	0.0508	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.019	0.0495	CbGbCtD
Levomilnacipran—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0186	0.0485	CbGbCtD
Levomilnacipran—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0166	0.0432	CbGbCtD
Levomilnacipran—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0162	0.0423	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0153	0.0399	CbGbCtD
Levomilnacipran—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00974	0.0253	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00919	0.0239	CbGbCtD
Levomilnacipran—Milnacipran—SLC6A4—chronic obstructive pulmonary disease	0.00252	0.717	CrCbGaD
Levomilnacipran—Pethidine—SLC6A4—chronic obstructive pulmonary disease	0.000652	0.186	CrCbGaD
Levomilnacipran—Pethidine—ALB—chronic obstructive pulmonary disease	0.000343	0.0976	CrCbGaD
Levomilnacipran—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000307	0.00217	CcSEcCtD
Levomilnacipran—Tension—Formoterol—chronic obstructive pulmonary disease	0.000307	0.00217	CcSEcCtD
Levomilnacipran—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000306	0.00217	CcSEcCtD
Levomilnacipran—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000306	0.00217	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.00216	CcSEcCtD
Levomilnacipran—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.00215	CcSEcCtD
Levomilnacipran—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000303	0.00215	CcSEcCtD
Levomilnacipran—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000299	0.00211	CcSEcCtD
Levomilnacipran—Hypercholesterolaemia—Prednisone—chronic obstructive pulmonary disease	0.000298	0.00211	CcSEcCtD
Levomilnacipran—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000297	0.0021	CcSEcCtD
Levomilnacipran—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00209	CcSEcCtD
Levomilnacipran—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000295	0.00209	CcSEcCtD
Levomilnacipran—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.00207	CcSEcCtD
Levomilnacipran—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000293	0.00207	CcSEcCtD
Levomilnacipran—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000291	0.00206	CcSEcCtD
Levomilnacipran—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000291	0.00206	CcSEcCtD
Levomilnacipran—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00205	CcSEcCtD
Levomilnacipran—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000289	0.00205	CcSEcCtD
Levomilnacipran—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000287	0.00203	CcSEcCtD
Levomilnacipran—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.00203	CcSEcCtD
Levomilnacipran—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000287	0.00203	CcSEcCtD
Levomilnacipran—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000286	0.00202	CcSEcCtD
Levomilnacipran—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000284	0.00201	CcSEcCtD
Levomilnacipran—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000281	0.00199	CcSEcCtD
Levomilnacipran—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000278	0.00197	CcSEcCtD
Levomilnacipran—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00196	CcSEcCtD
Levomilnacipran—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00196	CcSEcCtD
Levomilnacipran—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00196	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000274	0.00194	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000273	0.00193	CcSEcCtD
Levomilnacipran—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00192	CcSEcCtD
Levomilnacipran—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00192	CcSEcCtD
Levomilnacipran—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00027	0.00191	CcSEcCtD
Levomilnacipran—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00191	CcSEcCtD
Levomilnacipran—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00191	CcSEcCtD
Levomilnacipran—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000266	0.00188	CcSEcCtD
Levomilnacipran—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.00188	CcSEcCtD
Levomilnacipran—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000266	0.00188	CcSEcCtD
Levomilnacipran—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000265	0.00188	CcSEcCtD
Levomilnacipran—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000265	0.00188	CcSEcCtD
Levomilnacipran—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.00188	CcSEcCtD
Levomilnacipran—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000265	0.00188	CcSEcCtD
Levomilnacipran—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000265	0.00188	CcSEcCtD
Levomilnacipran—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00187	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00187	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00187	CcSEcCtD
Levomilnacipran—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00185	CcSEcCtD
Levomilnacipran—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00026	0.00184	CcSEcCtD
Levomilnacipran—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00026	0.00184	CcSEcCtD
Levomilnacipran—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00026	0.00184	CcSEcCtD
Levomilnacipran—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00184	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000259	0.00183	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000259	0.00183	CcSEcCtD
Levomilnacipran—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000258	0.00182	CcSEcCtD
Levomilnacipran—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.0018	CcSEcCtD
Levomilnacipran—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00179	CcSEcCtD
Levomilnacipran—Infection—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00179	CcSEcCtD
Levomilnacipran—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00178	CcSEcCtD
Levomilnacipran—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000251	0.00178	CcSEcCtD
Levomilnacipran—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00177	CcSEcCtD
Levomilnacipran—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00177	CcSEcCtD
Levomilnacipran—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00177	CcSEcCtD
Levomilnacipran—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00025	0.00177	CcSEcCtD
Levomilnacipran—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00176	CcSEcCtD
Levomilnacipran—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00176	CcSEcCtD
Levomilnacipran—Infection—Montelukast—chronic obstructive pulmonary disease	0.000248	0.00176	CcSEcCtD
Levomilnacipran—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00175	CcSEcCtD
Levomilnacipran—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00175	CcSEcCtD
Levomilnacipran—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000247	0.00175	CcSEcCtD
Levomilnacipran—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.00174	CcSEcCtD
Levomilnacipran—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00173	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00173	CcSEcCtD
Levomilnacipran—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00173	CcSEcCtD
Levomilnacipran—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00172	CcSEcCtD
Levomilnacipran—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00169	CcSEcCtD
Levomilnacipran—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.00169	CcSEcCtD
Levomilnacipran—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000238	0.00169	CcSEcCtD
Levomilnacipran—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000237	0.00394	CbGpPWpGaD
Levomilnacipran—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000237	0.00168	CcSEcCtD
Levomilnacipran—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.00168	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000237	0.00393	CbGpPWpGaD
Levomilnacipran—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00167	CcSEcCtD
Levomilnacipran—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00166	CcSEcCtD
Levomilnacipran—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00166	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000233	0.00387	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000233	0.00165	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00165	CcSEcCtD
Levomilnacipran—SLC6A2—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000232	0.00385	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000231	0.00384	CbGpPWpGaD
Levomilnacipran—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00163	CcSEcCtD
Levomilnacipran—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00163	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00023	0.00382	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.00023	0.00382	CbGpPWpGaD
Levomilnacipran—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00023	0.00163	CcSEcCtD
Levomilnacipran—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000229	0.00162	CcSEcCtD
Levomilnacipran—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000228	0.00378	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00161	CcSEcCtD
Levomilnacipran—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00161	CcSEcCtD
Levomilnacipran—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00161	CcSEcCtD
Levomilnacipran—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00161	CcSEcCtD
Levomilnacipran—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000226	0.0016	CcSEcCtD
Levomilnacipran—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.00159	CcSEcCtD
Levomilnacipran—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000225	0.00159	CcSEcCtD
Levomilnacipran—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000225	0.00159	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000224	0.00373	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000224	0.00159	CcSEcCtD
Levomilnacipran—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000224	0.00158	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000223	0.0037	CbGpPWpGaD
Levomilnacipran—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00157	CcSEcCtD
Levomilnacipran—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000222	0.00157	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000221	0.00367	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00156	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00156	CcSEcCtD
Levomilnacipran—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00022	0.00156	CcSEcCtD
Levomilnacipran—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00156	CcSEcCtD
Levomilnacipran—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00156	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.00364	CbGpPWpGaD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000218	0.00362	CbGpPWpGaD
Levomilnacipran—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00154	CcSEcCtD
Levomilnacipran—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00154	CcSEcCtD
Levomilnacipran—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00154	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000218	0.00362	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00153	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000216	0.00153	CcSEcCtD
Levomilnacipran—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000215	0.00152	CcSEcCtD
Levomilnacipran—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00152	CcSEcCtD
Levomilnacipran—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00152	CcSEcCtD
Levomilnacipran—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.00151	CcSEcCtD
Levomilnacipran—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.0015	CcSEcCtD
Levomilnacipran—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.0015	CcSEcCtD
Levomilnacipran—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00149	CcSEcCtD
Levomilnacipran—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00021	0.00149	CcSEcCtD
Levomilnacipran—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00148	CcSEcCtD
Levomilnacipran—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000209	0.00148	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.00148	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000209	0.00148	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00147	CcSEcCtD
Levomilnacipran—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00147	CcSEcCtD
Levomilnacipran—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00146	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000205	0.0034	CbGpPWpGaD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.0034	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00145	CcSEcCtD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000204	0.00339	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000204	0.00338	CbGpPWpGaD
Levomilnacipran—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00143	CcSEcCtD
Levomilnacipran—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00143	CcSEcCtD
Levomilnacipran—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00143	CcSEcCtD
Levomilnacipran—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00143	CcSEcCtD
Levomilnacipran—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00143	CcSEcCtD
Levomilnacipran—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00143	CcSEcCtD
Levomilnacipran—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000201	0.00142	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000201	0.00333	CbGpPWpGaD
Levomilnacipran—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.00141	CcSEcCtD
Levomilnacipran—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.00141	CcSEcCtD
Levomilnacipran—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000199	0.00141	CcSEcCtD
Levomilnacipran—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00141	CcSEcCtD
Levomilnacipran—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000198	0.0014	CcSEcCtD
Levomilnacipran—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000198	0.00329	CbGpPWpGaD
Levomilnacipran—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000198	0.0014	CcSEcCtD
Levomilnacipran—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000198	0.0014	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00139	CcSEcCtD
Levomilnacipran—SLC6A4—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000196	0.00325	CbGpPWpGaD
Levomilnacipran—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000195	0.00138	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000193	0.00321	CbGpPWpGaD
Levomilnacipran—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00135	CcSEcCtD
Levomilnacipran—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00135	CcSEcCtD
Levomilnacipran—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00135	CcSEcCtD
Levomilnacipran—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00019	0.00316	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000189	0.00314	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000188	0.00312	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00133	CcSEcCtD
Levomilnacipran—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00133	CcSEcCtD
Levomilnacipran—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000188	0.00133	CcSEcCtD
Levomilnacipran—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000187	0.00133	CcSEcCtD
Levomilnacipran—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000184	0.0013	CcSEcCtD
Levomilnacipran—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.0013	CcSEcCtD
Levomilnacipran—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000183	0.0013	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000182	0.00302	CbGpPWpGaD
Levomilnacipran—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00128	CcSEcCtD
Levomilnacipran—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00128	CcSEcCtD
Levomilnacipran—CYP2C8—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00018	0.00299	CbGpPWpGaD
Levomilnacipran—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00018	0.00299	CbGpPWpGaD
Levomilnacipran—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00127	CcSEcCtD
Levomilnacipran—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00126	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—APIP—chronic obstructive pulmonary disease	0.000178	0.00295	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00126	CcSEcCtD
Levomilnacipran—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00125	CcSEcCtD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000176	0.00293	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00124	CcSEcCtD
Levomilnacipran—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00124	CcSEcCtD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000174	0.00289	CbGpPWpGaD
Levomilnacipran—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00122	CcSEcCtD
Levomilnacipran—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00121	CcSEcCtD
Levomilnacipran—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00121	CcSEcCtD
Levomilnacipran—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00119	CcSEcCtD
Levomilnacipran—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00119	CcSEcCtD
Levomilnacipran—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000168	0.00279	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000166	0.00276	CbGpPWpGaD
Levomilnacipran—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000166	0.00275	CbGpPWpGaD
Levomilnacipran—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00117	CcSEcCtD
Levomilnacipran—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00117	CcSEcCtD
Levomilnacipran—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00117	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000164	0.00272	CbGpPWpGaD
Levomilnacipran—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
Levomilnacipran—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00115	CcSEcCtD
Levomilnacipran—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00115	CcSEcCtD
Levomilnacipran—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000161	0.00267	CbGpPWpGaD
Levomilnacipran—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00114	CcSEcCtD
Levomilnacipran—Rash—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00114	CcSEcCtD
Levomilnacipran—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00114	CcSEcCtD
Levomilnacipran—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00114	CcSEcCtD
Levomilnacipran—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00016	0.00113	CcSEcCtD
Levomilnacipran—Headache—Formoterol—chronic obstructive pulmonary disease	0.00016	0.00113	CcSEcCtD
Levomilnacipran—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00113	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00113	CcSEcCtD
Levomilnacipran—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00113	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00264	CbGpPWpGaD
Levomilnacipran—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000159	0.00112	CcSEcCtD
Levomilnacipran—Rash—Montelukast—chronic obstructive pulmonary disease	0.000158	0.00112	CcSEcCtD
Levomilnacipran—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00111	CcSEcCtD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000157	0.00261	CbGpPWpGaD
Levomilnacipran—Headache—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00111	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000156	0.0026	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000156	0.00259	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000155	0.00258	CbGpPWpGaD
Levomilnacipran—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00108	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000153	0.00253	CbGpPWpGaD
Levomilnacipran—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Levomilnacipran—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Levomilnacipran—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Levomilnacipran—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Levomilnacipran—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000151	0.00251	CbGpPWpGaD
Levomilnacipran—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.00107	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000149	0.00247	CbGpPWpGaD
Levomilnacipran—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
Levomilnacipran—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000148	0.00105	CcSEcCtD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.00246	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000148	0.00246	CbGpPWpGaD
Levomilnacipran—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Levomilnacipran—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.00103	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000145	0.0024	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.0024	CbGpPWpGaD
Levomilnacipran—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.00101	CcSEcCtD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00237	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00237	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000143	0.00237	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000141	0.00234	CbGpPWpGaD
Levomilnacipran—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000141	0.000995	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000139	0.00231	CbGpPWpGaD
Levomilnacipran—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000983	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000138	0.00229	CbGpPWpGaD
Levomilnacipran—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000962	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.000954	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.000945	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000132	0.0022	CbGpPWpGaD
Levomilnacipran—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000935	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000131	0.00218	CbGpPWpGaD
Levomilnacipran—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000928	CcSEcCtD
Levomilnacipran—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000907	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000128	0.00213	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00213	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.00212	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000127	0.0021	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000126	0.0021	CbGpPWpGaD
Levomilnacipran—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000884	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000878	CcSEcCtD
Levomilnacipran—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000876	CcSEcCtD
Levomilnacipran—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000871	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000118	0.00196	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00195	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000117	0.00194	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00194	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00194	CbGpPWpGaD
Levomilnacipran—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000821	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—GC—chronic obstructive pulmonary disease	0.000115	0.0019	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000114	0.0019	CbGpPWpGaD
Levomilnacipran—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000113	0.0008	CcSEcCtD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00187	CbGpPWpGaD
Levomilnacipran—Syncope—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000781	CcSEcCtD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.00011	0.00183	CbGpPWpGaD
Levomilnacipran—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000777	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000765	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000754	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000106	0.00177	CbGpPWpGaD
Levomilnacipran—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000752	CcSEcCtD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00175	CbGpPWpGaD
Levomilnacipran—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000739	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000736	CcSEcCtD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00172	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00172	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.00072	CcSEcCtD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000101	0.00168	CbGpPWpGaD
Levomilnacipran—Infection—Prednisone—chronic obstructive pulmonary disease	9.98e-05	0.000706	CcSEcCtD
Levomilnacipran—Shock—Prednisone—chronic obstructive pulmonary disease	9.88e-05	0.000699	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000697	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.000694	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—chronic obstructive pulmonary disease	9.75e-05	0.00069	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	9.72e-05	0.00161	CbGpPWpGaD
Levomilnacipran—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.71e-05	0.000687	CcSEcCtD
Levomilnacipran—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	9.67e-05	0.00161	CbGpPWpGaD
Levomilnacipran—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.57e-05	0.000677	CcSEcCtD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	9.46e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	9.44e-05	0.00157	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	9.34e-05	0.00155	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.27e-05	0.00154	CbGpPWpGaD
Levomilnacipran—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.14e-05	0.000647	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.13e-05	0.00152	CbGpPWpGaD
Levomilnacipran—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.08e-05	0.000643	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	9.06e-05	0.0015	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.03e-05	0.0015	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	9.02e-05	0.0015	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.02e-05	0.000638	CcSEcCtD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	8.97e-05	0.00149	CbGpPWpGaD
Levomilnacipran—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.84e-05	0.000626	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.73e-05	0.000618	CcSEcCtD
Levomilnacipran—Rash—Prednisolone—chronic obstructive pulmonary disease	8.71e-05	0.000617	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.7e-05	0.000616	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000613	CcSEcCtD
Levomilnacipran—Headache—Prednisolone—chronic obstructive pulmonary disease	8.66e-05	0.000613	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—chronic obstructive pulmonary disease	8.59e-05	0.000608	CcSEcCtD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.52e-05	0.00142	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	8.5e-05	0.00141	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.48e-05	0.00141	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	8.36e-05	0.00139	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.000581	CcSEcCtD
Levomilnacipran—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.21e-05	0.000581	CcSEcCtD
Levomilnacipran—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.15e-05	0.00135	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.06e-05	0.00134	CbGpPWpGaD
Levomilnacipran—Urticaria—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000565	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.000562	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.000562	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	7.91e-05	0.00131	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	7.67e-05	0.00127	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	7.63e-05	0.00127	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	7.59e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.59e-05	0.00126	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.5e-05	0.00125	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.48e-05	0.00124	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.41e-05	0.00123	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.4e-05	0.000524	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.2e-05	0.00051	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.000503	CcSEcCtD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	7.04e-05	0.00117	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.87e-05	0.00114	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.000486	CcSEcCtD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.78e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.77e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.68e-05	0.00111	CbGpPWpGaD
Levomilnacipran—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.64e-05	0.00047	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	6.43e-05	0.00107	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.42e-05	0.00107	CbGpPWpGaD
Levomilnacipran—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000452	CcSEcCtD
Levomilnacipran—Rash—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000448	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.33e-05	0.00105	CbGpPWpGaD
Levomilnacipran—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000448	CcSEcCtD
Levomilnacipran—Headache—Prednisone—chronic obstructive pulmonary disease	6.29e-05	0.000445	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.26e-05	0.00104	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.24e-05	0.00104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.23e-05	0.00103	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	6.22e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GCLC—chronic obstructive pulmonary disease	6.18e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.14e-05	0.00102	CbGpPWpGaD
Levomilnacipran—Nausea—Prednisone—chronic obstructive pulmonary disease	5.96e-05	0.000422	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.82e-05	0.000966	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.77e-05	0.000958	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.74e-05	0.000953	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.73e-05	0.000952	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.65e-05	0.000938	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.64e-05	0.000937	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.57e-05	0.000926	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.57e-05	0.000925	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.51e-05	0.000916	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	5.51e-05	0.000915	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.44e-05	0.000903	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	5.35e-05	0.000888	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	5.33e-05	0.000885	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.2e-05	0.000864	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.2e-05	0.000863	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.19e-05	0.000862	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	5.16e-05	0.000858	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.13e-05	0.000851	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.12e-05	0.000851	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	4.95e-05	0.000823	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.92e-05	0.000818	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.9e-05	0.000814	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.85e-05	0.000806	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.84e-05	0.000805	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	4.84e-05	0.000804	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.78e-05	0.000793	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.71e-05	0.000782	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.53e-05	0.000752	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.51e-05	0.000749	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.46e-05	0.000742	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.44e-05	0.000738	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	4.44e-05	0.000737	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.34e-05	0.00072	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.28e-05	0.00071	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	4.19e-05	0.000697	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.07e-05	0.000677	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.02e-05	0.000667	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.98e-05	0.000662	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.96e-05	0.000658	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.96e-05	0.000658	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	3.86e-05	0.000642	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	3.85e-05	0.000639	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.78e-05	0.000627	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.64e-05	0.000605	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	3.63e-05	0.000603	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	3.59e-05	0.000597	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.4e-05	0.000564	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.35e-05	0.000557	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.16e-05	0.000525	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.12e-05	0.000519	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.08e-05	0.000511	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.96e-05	0.000492	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.94e-05	0.000488	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.92e-05	0.000485	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.91e-05	0.000484	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	2.86e-05	0.000475	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.82e-05	0.000469	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.71e-05	0.00045	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.66e-05	0.000441	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.62e-05	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.6e-05	0.000432	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ALB—chronic obstructive pulmonary disease	2.57e-05	0.000426	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.56e-05	0.000425	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.55e-05	0.000424	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	2.49e-05	0.000414	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.46e-05	0.000408	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.41e-05	0.000401	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.38e-05	0.000395	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.37e-05	0.000394	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.35e-05	0.00039	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.32e-05	0.000385	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.18e-05	0.000362	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.12e-05	0.000352	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.07e-05	0.000344	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.99e-05	0.00033	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.9e-05	0.000315	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.89e-05	0.000314	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.86e-05	0.000309	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.77e-05	0.000295	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.58e-05	0.000262	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.56e-05	0.00026	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.56e-05	0.000259	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	1.54e-05	0.000256	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.53e-05	0.000255	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.44e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.43e-05	0.000237	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000234	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.39e-05	0.000232	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.38e-05	0.000229	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.36e-05	0.000226	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.34e-05	0.000223	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.000216	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.28e-05	0.000213	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.28e-05	0.000213	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.27e-05	0.00021	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.26e-05	0.000209	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.23e-05	0.000204	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.19e-05	0.000198	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.16e-05	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000192	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.13e-05	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.08e-05	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.07e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.95e-06	0.000165	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.66e-06	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.53e-06	0.000158	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.43e-06	0.000157	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.43e-06	0.000157	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.3e-06	0.000154	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.89e-06	0.000148	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.88e-06	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.76e-06	0.000146	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.67e-06	0.000144	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.42e-06	0.00014	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.38e-06	0.000139	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.29e-06	0.000138	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.22e-06	0.000136	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.17e-06	0.000136	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.74e-06	0.000129	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.56e-06	0.000126	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.97e-06	0.000116	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	6.41e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	6.13e-06	0.000102	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.81e-06	9.65e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.73e-06	9.52e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.72e-06	9.5e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	5.58e-06	9.28e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	5.47e-06	9.09e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.34e-06	8.87e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.34e-06	8.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.26e-06	8.74e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.06e-06	8.41e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.03e-06	8.36e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.44e-06	5.71e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.29e-06	5.47e-05	CbGpPWpGaD
